Rheumatoid Arthritis Guideline

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis Guideline Supplementary Appendix 1 – Methods

Rheumatoid Arthritis Guideline Supplementary Appendix 2 – Evidence Report

Rheumatoid Arthritis Guideline Supplementary Appendix 3 – Clinical Outcomes

Rheumatoid Arthritis Guideline Supplementary Appendix 4 – Medication Cost Estimates

Rheumatoid Arthritis Guideline Supplementary Appendix 5 – Panel/Teams Involved

Rheumatoid Arthritis Guideline Supplementary Appendix 6 – Study Selection Process

Rheumatoid Arthritis Guideline Supplementary Appendix 7 – Search Strategies

Rheumatoid Arthritis Guideline Project Plan

Rheumatoid Arthritis Guideline Project Plan Public Comments

Rheumatoid Arthritis Guideline Author Response to Public Comments

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis Guideline Supplementary Appendix 1 – Evidence Report

Rheumatoid Arthritis Guideline Supplementary Appendix 2 – Search Strategies

Rheumatoid Arthritis Guideline Supplementary Appendix 3 – Study Selection Process

Rheumatoid Arthritis Guideline Supplementary Appendix 4 – Dropped Recommendation Statements

Rheumatoid Arthritis Guideline Supplementary Appendix 5 – Executive Summary 

Rheumatoid Arthritis Guideline Project Plan

Rheumatoid Arthritis Guideline Disclosure Summary

2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis Disease Activity Measures: American College of Rheumatology Recommendations for Use in Clinical Practice

American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis